Role of genetics in the development of cardiac allograft vasculopathy.
Journal
Bratislavske lekarske listy
ISSN: 0006-9248
Titre abrégé: Bratisl Lek Listy
Pays: Slovakia
ID NLM: 0065324
Informations de publication
Date de publication:
2023
2023
Historique:
pubmed:
5
1
2023
medline:
14
2
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
The association between genetic polymorphisms and early cardiac allograft vasculopathy (CAV) development is relatively unexplored. Identification of genes involved in the CAV process may offer new insights into pathophysiology and lead to a wider range of therapeutic options. This prospective study of 109 patients investigated 44 single nucleotide polymorphisms (SNPs) within the susceptibility loci potentially related to coronary artery disease, carotid artery intima-media thickness (cIMT), and in nitric oxide synthase gene. Genotyping was done by the Fluidigm SNP Type assays and Fluidigm 48.48 Dynamic Array IFC. The intima thickness progression (IT) was evaluated by coronary optical coherence tomography performed 1 month and 12 months after heart transplantation (HTx). During the first post-HTx year, the mean intima thickness (IT) increased by 24.0 ± 34.2 µm (p < 0.001) and lumen area decreased by ‒0.9 ± 1.8 mm2 (p < 0.001). The rs1570360 (A/G) SNP of the vascular endothelial growth factor A (VEGFA) gene showed the strongest association with intima thickness progression, even in the presence of the traditional CAV risk factors. SNPs previously related to carotid artery intima-media thickness rs11785239 (PRAG1), rs6584389 (PAX2), rs13225723 (LINC02577) and rs17477177 (CCDC71L), were among the five most significantly associated with IT progression but lost their significance once traditional CAV risk factors had been added. Results of this study suggest that genetic variability may play an important role in CAV development. The vascular endothelial growth factor A gene SNP rs1570360 showed the strongest association with intima thickness (IT) progression measured by OCT, even in the presence of the traditional CAV risk factors (Tab. 3, Fig. 3, Ref. 36). Text in PDF www.elis.sk Keywords: cardiac allograft vasculopathy, optical coherence tomography, vascular endothelial growth factor A, intimal thickening, genetic polymorphism.
Sections du résumé
BACKGROUND
BACKGROUND
The association between genetic polymorphisms and early cardiac allograft vasculopathy (CAV) development is relatively unexplored. Identification of genes involved in the CAV process may offer new insights into pathophysiology and lead to a wider range of therapeutic options.
METHODS
METHODS
This prospective study of 109 patients investigated 44 single nucleotide polymorphisms (SNPs) within the susceptibility loci potentially related to coronary artery disease, carotid artery intima-media thickness (cIMT), and in nitric oxide synthase gene. Genotyping was done by the Fluidigm SNP Type assays and Fluidigm 48.48 Dynamic Array IFC. The intima thickness progression (IT) was evaluated by coronary optical coherence tomography performed 1 month and 12 months after heart transplantation (HTx).
RESULTS
RESULTS
During the first post-HTx year, the mean intima thickness (IT) increased by 24.0 ± 34.2 µm (p < 0.001) and lumen area decreased by ‒0.9 ± 1.8 mm2 (p < 0.001). The rs1570360 (A/G) SNP of the vascular endothelial growth factor A (VEGFA) gene showed the strongest association with intima thickness progression, even in the presence of the traditional CAV risk factors. SNPs previously related to carotid artery intima-media thickness rs11785239 (PRAG1), rs6584389 (PAX2), rs13225723 (LINC02577) and rs17477177 (CCDC71L), were among the five most significantly associated with IT progression but lost their significance once traditional CAV risk factors had been added.
CONCLUSION
CONCLUSIONS
Results of this study suggest that genetic variability may play an important role in CAV development. The vascular endothelial growth factor A gene SNP rs1570360 showed the strongest association with intima thickness (IT) progression measured by OCT, even in the presence of the traditional CAV risk factors (Tab. 3, Fig. 3, Ref. 36). Text in PDF www.elis.sk Keywords: cardiac allograft vasculopathy, optical coherence tomography, vascular endothelial growth factor A, intimal thickening, genetic polymorphism.
Identifiants
pubmed: 36598310
doi: 10.4149/BLL_2023_031
pmc: PMC10517863
mid: NIHMS1930088
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-200Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB004640
Pays : United States
Références
BMC Med Genet. 2018 Jul 4;19(1):108
pubmed: 29973139
Am J Transplant. 2004 Jun;4(6):962-70
pubmed: 15147431
J Heart Lung Transplant. 2017 Apr;36(4):434-442
pubmed: 27865734
J Am Soc Nephrol. 2002 Jan;13(1):260-264
pubmed: 11752046
Int J Cardiovasc Imaging. 2023 Feb;39(2):257-268
pubmed: 36109445
Circulation. 2002 May 28;105(21):2524-30
pubmed: 12034660
Eur Neurol. 2011;66(1):47-52
pubmed: 21757917
J Heart Lung Transplant. 2019 Oct;38(10):1056-1066
pubmed: 31548031
Circ Res. 1998 Oct 19;83(8):832-40
pubmed: 9776730
Transpl Int. 2018 Mar;31(3):278-290
pubmed: 29363220
J Biol Chem. 2001 Mar 9;276(10):7614-20
pubmed: 11108718
Transpl Immunol. 2021 Apr;65:101340
pubmed: 33069814
J Heart Lung Transplant. 2018 Sep;37(9):1075-1082
pubmed: 29954686
J Heart Lung Transplant. 2006 Jun;25(6):690-8
pubmed: 16730575
Circulation. 1996 Apr 15;93(8):1493-5
pubmed: 8608615
IEEE Trans Med Imaging. 2013 Aug;32(8):1536-49
pubmed: 23649180
J Physiol Sci. 2014 Jan;64(1):73-6
pubmed: 24097272
Circulation. 1996 Sep 1;94(5):1074-82
pubmed: 8790049
Med Image Anal. 2018 Dec;50:95-105
pubmed: 30253306
J Heart Lung Transplant. 2016 Sep;35(9):1124-30
pubmed: 27266812
Cardiovasc Res. 2021 Nov 22;117(13):2624-2638
pubmed: 34343276
J Heart Lung Transplant. 2018 Aug;37(8):992-1000
pubmed: 29706574
Circ Heart Fail. 2018 Sep;11(9):e004050
pubmed: 30354362
J Heart Lung Transplant. 2013 Jan;32(1):120-8
pubmed: 23260712
Clin Transplant. 2020 Sep;34(9):e13984
pubmed: 32445429
JACC Heart Fail. 2013 Oct;1(5):389-99
pubmed: 24621971
Transplantation. 2008 Oct 15;86(7):991-7
pubmed: 18852667
Ann Clin Lab Sci. 2017 Mar;47(2):144-155
pubmed: 28442515
Ultrasound Med Biol. 2013 Jan;39(1):72-88
pubmed: 23141901
Microvasc Res. 1999 Sep;58(2):128-36
pubmed: 10458928
Heart. 2022 Apr;108(8):586-592
pubmed: 34340994
Transplantation. 2003 Jul 15;76(1):224-30
pubmed: 12865814
Iran J Immunol. 2009 Sep;6(3):119-29
pubmed: 19801785